❭ Research by medical division ❭ Cancer Medicine ❭ Institute for Cancer Research ❭ Dept. of Cancer Genetics ❭ Translational studies on solid tumours [Helland] ❭ Clinical trials ❭ DART ❭

Durvalumab After chemoRadioTherapy for NSCLC patients

– a phase II translational and biomarker study investigating PDL1 positive and negative patients

  • EudraCT number: 2019-002537-11
  • Clinicaltrials.gov: NCT04392505
Background/study objectives
Study design
Collaborative partners
Update/publications
 
Scroll to top

Home Dept. of Cancer Genetics Translational studies on solid tumours [Helland]

  • Group members
  • Clinical trials
    • DART
    • NIPU
    • COM-IT-2
    • MATRIX-RARE
    • IMPRESS-Norway
  • Translational studies
  • Publications
  • News

Recent publications

Henkel PS, Aas E, Russnes HG, Dyvik I, Fagereng GL, Helland Å, Røgenes H, Lien TG, Pedersen K (2025)
Micro-costing Study of Genomic Profiling for Precision Cancer Medicine: Application from the National Infrastructure for Precision Diagnostics in Norway
J Mol Diagn (in press)
DOI 10.1016/j.jmoldx.2025.06.006, PubMed 40712993

Hermansen JU, Athanasiadis P, Yin Y, Rise AF, Arribas AJ, Cascione L, Russnes HG, Helland Å, Mato AR, Bertoni F, Tjønnfjord GE, Aittokallio T, Skånland SS (2025)
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient
Cell Death Dis, 16 (1), 555
DOI 10.1038/s41419-025-07884-7, PubMed 40701968

Stålberg SM, Silwal-Pandit L, Hamfjord J, Nebdal DJH, Lehtiö J, Lingjærde OC, Skålhegg BS, Kure EH (2025)
Elevated KRAS protein level is associated with better survival in pancreatic cancer
BMC Cancer, 25 (1), 1080
DOI 10.1186/s12885-025-14461-w, PubMed 40596921

More publications

Oslo University Hospital is a part of Southern and Eastern Norway Regional Health Authority.

Webmaster for research pages: Trond Olav Berg

Cookie policy

Accessibility statement (in Norwegian)